125 related articles for article (PubMed ID: 23411412)
1. Neuropeptide S inhibits release of 5-HT and glycine in mouse amygdala and frontal/prefrontal cortex through activation of the neuropeptide S receptor.
Gardella E; Romei C; Cavallero A; Trapella C; Fedele E; Raiteri L
Neurochem Int; 2013 Mar; 62(4):360-6. PubMed ID: 23411412
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings.
Raiteri L; Luccini E; Romei C; Salvadori S; Calò G
Br J Pharmacol; 2009 Jun; 157(3):474-81. PubMed ID: 19371348
[TBL] [Abstract][Full Text] [Related]
3. Central Neuropeptide S inhibits food intake in mice through activation of Neuropeptide S receptor.
Peng YL; Han RW; Chang M; Zhang L; Zhang RS; Li W; Han YF; Wang R
Peptides; 2010 Dec; 31(12):2259-63. PubMed ID: 20800637
[TBL] [Abstract][Full Text] [Related]
4. Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals.
Grilli M; Neri E; Zappettini S; Massa F; Bisio A; Romussi G; Marchi M; Pittaluga A
Neuropharmacology; 2009; 57(5-6):523-30. PubMed ID: 19628000
[TBL] [Abstract][Full Text] [Related]
5. [tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies.
Ruzza C; Rizzi A; Camarda V; Pulga A; Marzola G; Filaferro M; Novi C; Ruggieri V; Marzola E; Vitale G; Salvadori S; Guerrini R; Calo' G
Peptides; 2012 Apr; 34(2):404-11. PubMed ID: 22342393
[TBL] [Abstract][Full Text] [Related]
6. Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice.
Ambar G; Chiavegatto S
Genes Brain Behav; 2009 Mar; 8(2):161-73. PubMed ID: 19055689
[TBL] [Abstract][Full Text] [Related]
7. Diabetes attenuates psychological stress-elicited 5-HT secretion in the prefrontal cortex but not in the amygdala of mice.
Miyata S; Yamada N; Hirano S; Tanaka S; Kamei J
Brain Res; 2007 May; 1147():233-9. PubMed ID: 17320057
[TBL] [Abstract][Full Text] [Related]
8. Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68.
Ruzza C; Rizzi A; Trapella C; Pela' M; Camarda V; Ruggieri V; Filaferro M; Cifani C; Reinscheid RK; Vitale G; Ciccocioppo R; Salvadori S; Guerrini R; Calo' G
Peptides; 2010 May; 31(5):915-25. PubMed ID: 20172007
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects.
Xu YL; Reinscheid RK; Huitron-Resendiz S; Clark SD; Wang Z; Lin SH; Brucher FA; Zeng J; Ly NK; Henriksen SJ; de Lecea L; Civelli O
Neuron; 2004 Aug; 43(4):487-97. PubMed ID: 15312648
[TBL] [Abstract][Full Text] [Related]
10. Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain.
Xu YL; Gall CM; Jackson VR; Civelli O; Reinscheid RK
J Comp Neurol; 2007 Jan; 500(1):84-102. PubMed ID: 17099900
[TBL] [Abstract][Full Text] [Related]
11. Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: a microdialysis study.
Ortega JE; Katner J; Davis R; Wade M; Nisenbaum L; Nomikos GG; Svensson KA; Perry KW
J Neurosci Res; 2012 Mar; 90(3):588-96. PubMed ID: 22038504
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor.
Ruzza C; Asth L; Guerrini R; Trapella C; Gavioli EC
Neuropharmacology; 2015 Oct; 97():1-6. PubMed ID: 25979487
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1.
Camarda V; Ruzza C; Rizzi A; Trapella C; Guerrini R; Reinscheid RK; Calo G
Peptides; 2013 Oct; 48():27-35. PubMed ID: 23911665
[TBL] [Abstract][Full Text] [Related]
14. Central Neuropeptide S inhibits distal colonic transit through activation of central Neuropeptide S receptor in mice.
Han RW; Chang M; Peng YL; Qiao LY; Yin XQ; Li W; Wang R
Peptides; 2009 Jul; 30(7):1313-7. PubMed ID: 19540430
[TBL] [Abstract][Full Text] [Related]
15. The role of the dorsomedial part of the prefrontal cortex serotonergic innervation in rat responses to the aversively conditioned context: behavioral, biochemical and immunocytochemical studies.
Lehner M; Taracha E; Turzyńska D; Sobolewska A; Hamed A; Kołomańska P; Skórzewska A; Maciejak P; Szyndler J; Bidziński A; Płaźnik A
Behav Brain Res; 2008 Oct; 192(2):203-15. PubMed ID: 18499280
[TBL] [Abstract][Full Text] [Related]
16. Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways.
Fantin M; Fischetti C; Trapella C; Morari M
Br J Pharmacol; 2007 Oct; 152(4):549-55. PubMed ID: 17618307
[TBL] [Abstract][Full Text] [Related]
17. Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor.
Guerrini R; Salvadori S; Rizzi A; Regoli D; Calo' G
Med Res Rev; 2010 Sep; 30(5):751-77. PubMed ID: 19824051
[TBL] [Abstract][Full Text] [Related]
18. Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neuropsychiatric disorders.
Petkova-Kirova P; Rakovska A; Zaekova G; Ballini C; Corte LD; Radomirov R; Vágvölgyi A
Neurochem Int; 2008 Dec; 53(6-8):355-61. PubMed ID: 18835308
[TBL] [Abstract][Full Text] [Related]
19. Tonic and phasic alteration in amygdala 5-HT, glutamate and GABA transmission after prefrontal cortex damage in rats.
Gonzalez LE; Quiñonez B; Rangel A; Pino S; Hernandez L
Brain Res; 2004 Apr; 1005(1-2):154-63. PubMed ID: 15044074
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
Amargós-Bosch M; Adell A; Artigas F
J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
